SITAGLIPTIN MARKET

INTRODUCTION

Sitagliptin, sold under the brand name Januvia among others, is an anti-diabetic medication used to treat type two diabetes. In the United Kingdom it is listed as less preferred than metformin or a sulfonylurea. It is taken by mouth. It is also available in the fixed-dose combination medication sitagliptin/metformin (Janumet, Janumet XR).

Common side effects include headaches, swelling of the legs, and upper respiratory tract infections. Serious side effects may include angioedema, low blood sugar, kidney problems, pancreatitis, and joint pain. Whether use in pregnancy or breastfeeding is safe is unclear. It is in the dipeptidyl peptidase-4 (DPP-4) inhibitor class and works by increasing the production of insulin and decreasing the production of glucagon by the pancreas.

Adverse effects from sitagliptin are similar to placebo, except for rare nausea, common cold-like symptoms, and photosensitivity. It does not increase the risk of diarrhea. No significant difference exists in the occurrence of hypoglycemia between placebo and sitagliptin. In those taking sulphonyl lure as, the risk of low blood sugar is increased. 

SITAGLIPTIN MARKET SIZE AND FORECAST

The Global Sitagliptin Market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.

SITAGLIPTIN MARKET NEW PRODUCT LAUNCH

Net meds SitagliptinSITAGLIPTIN belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors used in treating type 2 diabetes in adults. SITAGLIPTIN is prescribed for the condition of type 2 diabetes when diet and exercise alone cannot control their blood sugar levels. It is the first-line therapy for patients with type 2 diabetes that restores the body's response to insulin.

Insulin is the hormone that controls sugar levels in your blood. People with type 2 diabetes either do not produce enough insulin, or the insulin produced cannot perform its function in the body (insulin resistance).

Middle-aged or older individuals are most likely to suffer from type 2 diabetes, so it is also known as adult-onset diabetes.

SITAGLIPTIN contains sitagliptin. SITAGLIPTIN work by blocking the action of DPP-4 (an enzyme which destroys the hormone 'Incretin'). The enzyme 'Incretins' helps produce more insulin only when required and reduces blood sugar produced by the liver when not needed.

SITAGLIPTIN should be taken with food or an empty stomach. However, it should be taken at the same time of the day each time for the best results. For better advice, your doctor will decide what dose should be taken, which can change quickly depending on your condition.

The most common side effect of SITAGLIPTIN is hypo glycaemia (low blood glucose levels), upper respiratory tract infection, nasopharyngitis (infection of the nose and throat with common cold) and headache.

SITAGLIPTIN MARKET COMPANY PROFILE

• DR REDDY
• SUN PHARMA
• ALKEM
• Divislab
• Glaxo

THIS SITAGLIPTIN MARKET REPORT WILL ANSWER FOLLOWING QUESTIONS

1. How many Sitagliptin are manufactured per annum globally? Who are the sub-component suppliers in different regions?
2. Cost breakup of a Global Sitagliptin and key vendor selection criteria
3. Where is the Sitagliptin manufactured? What is the average margin per unit?
4. Market share of Global Sitagliptin market manufacturers and their upcoming products
5. Cost advantage for OEMs who manufacture Global Sitagliptin in-house
6. key predictions for next 5 years in Global Sitagliptin market
7. Average B-2-B Sitagliptin market price in all segments
8. Latest trends in Sitagliptin market, by every market segment
9. The market size (both volume and value) of the Sitagliptin market in 2024-2030 and every year in between?
10. Production breakup of Sitagliptin market, by suppliers and their OEM relationship